Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8018454,EC50,"Using the sigmoidal Emax model the mean serum concentration of azapropazone inhibiting platelet TXB2 generation by 50% (EC50) was found to be 98.1 +/- 41.9 (s.d.) micrograms ml-1, a value 1000 times higher than that for rac-ketorolac.",Effects on platelet functions and pharmacokinetics of azapropazone and ketorolac tromethamine given as single parenteral doses. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8018454/),[μg] / [ml],98.1,5123,DB00465,Ketorolac
,3264245,terminal half-life,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,5.09,8082,DB00465,Ketorolac
,3264245,plasma clearance (CL,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[ml] / [kg·min],0.35,8083,DB00465,Ketorolac
,3264245,tissue distribution (Vss,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.11,8084,DB00465,Ketorolac
,3264245,V beta,"The kinetics of i.v. ketorolac were characterized by a terminal half-life of 5.09 h, a small plasma clearance (CL = 0.35 ml.min-1.kg-1) and a small tissue distribution (Vss = 0.11 l.kg-1, V beta = 0.17 l.kg-1; mean (SD).","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[l] / [kg],0.17,8085,DB00465,Ketorolac
,3264245,peak levels,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),[μg] / [ml],0.8,8086,DB00465,Ketorolac
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.8,8087,DB00465,Ketorolac
,3264245,tmax,"Following i.m. and p.o. administration, peak levels of approximately 0.8 microgram/ml were rapidly attained (tmax = 0.8 and 0.9 h, respectively) and the systemic bioavailability was essentially complete.","Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264245/),h,0.9,8088,DB00465,Ketorolac
,19300040,clearance,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),[ml] / [kg(0.75·min],2.8,8619,DB00465,Ketorolac
,19300040,intercompartmental clearance,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),[ml] / [min],11.5,8620,DB00465,Ketorolac
,19300040,volume of distribution of the central compartment,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),ml,535,8621,DB00465,Ketorolac
,19300040,volume of distribution of the peripheral compartment,"Estimated parameters were clearance [2.8 mL x min(-1) x (kg(0.75))(-1)], intercompartmental clearance (11.5 mL/min), volume of distribution of the central compartment (535 mL), and volume of distribution of the peripheral compartment (322 mL).",Population pharmacokinetics of ketorolac in neonates and young infants. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300040/),ml,322,8622,DB00465,Ketorolac
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.9,9597,DB00465,Ketorolac
,2717521,AUC ratios,"The amount of PHK circulating in plasma was very low as judged by AUC ratios (PHK/K x 100) of 1.9 and 1.5% for the 30-mg po and im doses, respectively.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),%,1.5,9598,DB00465,Ketorolac
,2717521,plasma half-life,"The mean plasma half-life of K was remarkably consistent between po and im administration and was independent of dose, ranging from 5.21 to 5.56 hr.",Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2717521/),h,5.21 to 5.56,9599,DB00465,Ketorolac
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.20,17443,DB00465,Ketorolac
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.18,17444,DB00465,Ketorolac
,8801333,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 0.20, 0.18, and 0.82 microgram/mL for TD-A, TD-B, and TD-C, respectively.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),[μg] / [ml],0.82,17445,DB00465,Ketorolac
,8801333,terminal half-life,"The total AUC values for the concentration-time curves were TD-C > TD-A > TD-B, and the terminal half-life ranged from 6.6 to 9.7 h.","Transdermal delivery of ketorolac tromethamine: permeation enhancement, device design, and pharmacokinetics in healthy humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8801333/),h,6.6 to 9.7,17446,DB00465,Ketorolac
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],45.9,20885,DB00465,Ketorolac
,8148223,clearance,The mean +/- s.d. clearance of (S)-ketorolac (45.9 +/- 10.1 ml h-1 kg-1) exceeded (P = 0.0032) that of the (R)-enantiomer (19.0 +/- 5.0 ml h-1 kg-1).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[ml] / [h·kg],19.0,20886,DB00465,Ketorolac
,8148223,AUC ratio,The mean +/- s.d. AUC ratio for (S)-ketorolac:(R)-ketorolac (0.442 +/- 0.043) was significantly different from unity (P = 0.0001).,The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),,0.442,20887,DB00465,Ketorolac
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.135,20888,DB00465,Ketorolac
,8148223,steady-state volume of distribution,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),[l] / [kg],0.075,20889,DB00465,Ketorolac
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,2.35,20890,DB00465,Ketorolac
,8148223,half-lives,"The steady-state volume of distribution of (S)-ketorolac (0.135 +/- 0.022 l kg-1) was significantly different (P = 0.0013) from that of its optical antipode (0.075 +/- 0.014 l kg-1) and the half-lives of (S)- and (R)-ketorolac (2.35 +/- 0.23 h and 3.62 +/- 0.79 h, respectively) were also significantly different (P = 0.026).",The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8148223/),h,3.62,20891,DB00465,Ketorolac
,11195429,absolute bioavailability,A nasal spray formulation of ketorolac tromethamine showed the highest absorption with an absolute bioavailability of 91%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,91,32893,DB00465,Ketorolac
,11195429,absolute bioavailability,The absolute bioavailability of a solution of ketorolac acid was 70%.,Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,70,32894,DB00465,Ketorolac
,11195429,absolute bioavailability,"Interestingly, the absolute bioavailability of ketorolac tromethamine from a powder formulation is only 38%, indicating that the drug may not be totally released from the polymer matrix before it is removed from nasal epithelium by mucociliary clearance.",Development and evaluation of nasal formulations of ketorolac. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11195429/),%,38,32895,DB00465,Ketorolac
,33833624,elimination half-life,"Ketorolac exhibits rapid elimination of the analgesia-producing S (-) isomer, elimination half-life of 0.83 hours.",Ketorolac in Postoperative Neonates and Infants: A Systematic Review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33833624/),h,0.83,35413,DB00465,Ketorolac
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,75,35960,DB00465,Ketorolac
>,22334358,recoveries,The recoveries from spiked control samples were >75% for MFX and >79% for KTC.,Development and validation of liquid chromatography-mass spectrometric method for simultaneous determination of moxifloxacin and ketorolac in rat plasma: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22334358/),%,79,35961,DB00465,Ketorolac
,10079499,AUC S/R,"After the racemate, R-KT was predominant in plasma (AUC S/R, 0.45).",Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10079499/),,0.45,40282,DB00465,Ketorolac
,23199134,drug release,"From the in vitro dissolution study, optimized formulation F3 showed negligible drug release (6.75 ± 0.49%) in the initial lag period followed by slow release (97.47 ± 0.93%) for 24 h which clearly indicates that the drug is delivered to the colon.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),%,6.75,42663,DB00465,Ketorolac
,23199134,peak plasma concentration (C(max)),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[ng] / [ml],4482.74,42664,DB00465,Ketorolac
,23199134,C(max),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[ng] / [ml],3562.67,42665,DB00465,Ketorolac
,23199134,T(max),"From the pharmacokinetic evaluation, the immediate-release tablets producing peak plasma concentration (C(max)) was 4482.74 ng/ml at 2 h T(max) and colon-targeted tablets showed C(max) = 3562.67 ng/ml at 10 h T(max).","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),,10,42666,DB00465,Ketorolac
,23199134,area under the curve,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[h·ng] / [ml],10595.14,42667,DB00465,Ketorolac
,23199134,area under the curve,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),[h·ng] / [ml],18796.70,42668,DB00465,Ketorolac
,23199134,resident time,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),h,3.82,42669,DB00465,Ketorolac
,23199134,resident time,"The area under the curve for the immediate-release and compression-coated tablets was 10595.14 and 18796.70 ng h/ml and the mean resident time was 3.82 and 10.75 h, respectively.","Development, evaluation and pharmacokinetics of time-dependent ketorolac tromethamine tablets. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23199134/),h,10.75,42670,DB00465,Ketorolac
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.26,58983,DB00465,Ketorolac
,8592665,AUC S/R,"In both humans and rats, the pharmacokinetics of racemic KT were stereoselective with the R enantiomer being predominant (AUC S/R: humans, 0.26; Rats: 0.45).",The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,0.45,58984,DB00465,Ketorolac
,8592665,unbound S/R,This is likely due to more extensive plasma protein binding of S than its antipode (unbound S/R: 1.35).,The problem of racemization in the stereospecific assay and pharmacokinetic evaluation of ketorolac in human and rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8592665/),,1.35,58985,DB00465,Ketorolac
,8749226,half-life,"Then, concentrations decayed with a half-life of about 6 h.",Pharmacokinetics of oral ketorolac in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8749226/),h,6,60902,DB00465,Ketorolac
,17192497,tmax,"The i.n. ketorolac was rapidly and well absorbed (median tmax, 0.50-0.75 hours), and the half-life was approximately 5 to 6 hours, values that were similar to those following i.m. administration.",Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),h,0.50-0.75,61122,DB00465,Ketorolac
,17192497,half-life,"The i.n. ketorolac was rapidly and well absorbed (median tmax, 0.50-0.75 hours), and the half-life was approximately 5 to 6 hours, values that were similar to those following i.m. administration.",Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),h,5 to 6,61123,DB00465,Ketorolac
,17192497,Relative bioavailability,Relative bioavailability of i.n. compared to i.m. administration at the same doses was approximately 67% to 75%.,Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),%,67,61124,DB00465,Ketorolac
,17192497,Relative bioavailability,Relative bioavailability of i.n. compared to i.m. administration at the same doses was approximately 67% to 75%.,Pharmacokinetics and safety of ketorolac following single intranasal and intramuscular administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192497/),%,75,61125,DB00465,Ketorolac
,31419586,Permeability,"Permeability of small molecules was 10-6-10-5 cm/s showing 13-15 fold range of outward and inward permeation, while permeability of bevacizumab was lower by 2-3 orders of magnitude.",Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419586/),[cm] / [s],10-6-10-5,62128,DB00465,Ketorolac
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],3.6,65584,DB00465,Ketorolac
,33153182,ED30,"According to the isobolographic analysis, the experimental and theoretical ED30 values were similar for methyleugenol plus diclofenac, suggesting an additive effect, but significantly different for methyleugenol plus ketorolac (3.6 ± 0.5 vs. 7.7 ± 0.6 mg/kg, respectively), indicating a probable synergistic interaction.",Antinociceptive Interaction and Pharmacokinetics of the Combination Treatments of Methyleugenol Plus Diclofenac or Ketorolac. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33153182/),[mg] / [kg],7.7,65585,DB00465,Ketorolac
,22467894,clearance (CL/F),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),[l] / [h],2.05,67574,DB00465,Ketorolac
,22467894,volume of distribution (V/F),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),l,15.2,67575,DB00465,Ketorolac
,22467894,absorption half-life (t(1/2)abs),"Population parameter estimates (between subject variability) were clearance (CL/F) 2.05 L/h (60.5%), volume of distribution (V/F) 15.2 L (32.4%), absorption half-life (t(1/2)abs) 0.173 hour (25.0%).",The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),h,0.173,67576,DB00465,Ketorolac
,22467894,Time to peak concentration (Tmax),Time to peak concentration (Tmax) was 52 minutes (SD 6 minutes).,The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22467894/),min,52,67577,DB00465,Ketorolac
,23791718,permeation,"Iontophoretic permeation of KT from a 2% hydroxymethyl cellulose gel was comparable to that from an aqueous solution with equivalent drug loading (584.59±114.67 and 462.05±66.56μg/cm(2), respectively).",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],584.59,67787,DB00465,Ketorolac
,23791718,permeation,"Iontophoretic permeation of KT from a 2% hydroxymethyl cellulose gel was comparable to that from an aqueous solution with equivalent drug loading (584.59±114.67 and 462.05±66.56μg/cm(2), respectively).",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],462.05,67788,DB00465,Ketorolac
,23791718,Cumulative permeation,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],462.05,67789,DB00465,Ketorolac
,23791718,Cumulative permeation,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],416.28,67790,DB00465,Ketorolac
,23791718,steady state flux,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2)h],106.72,67791,DB00465,Ketorolac
,23791718,steady state flux,"Cumulative permeation (462.05±66.56 and 416.28±95.71μg/cm(2)) and steady state flux (106.72±11.70 and 94.28±15.47μg/cm(2)h), across porcine and human skin, were statistically equivalent confirming the validity of the model.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2)h],94.28,67792,DB00465,Ketorolac
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],91.04,67793,DB00465,Ketorolac
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),[μg] / [cm(2],20.16,67794,DB00465,Ketorolac
,23791718,KT,"Iontophoretic administration for 30min was superior to passive topical delivery for 1h and resulted in statistically significant increases in KT levels in the skin (91.04±15.48 vs. 20.16±8.58μg/cm(2)), in the biceps femoris at the treatment site (TM; 6.74±3.80 vs.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),,6.74,67795,DB00465,Ketorolac
,23791718,ratio,"In addition to increasing bioavailability, iontophoretic administration of KT showed clear selectivity for local delivery to the biceps femoris at the treatment site - the TM:NTM ratio was 5.26±1.45, and the TM:P and NTM:P ratios were 0.75±0.32 and 0.14±0.04, respectively.",Iontophoretic transport kinetics of ketorolac in vitro and in vivo: demonstrating local enhanced topical drug delivery to muscle. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23791718/),,5,67796,DB00465,Ketorolac
,21233498,clearance,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.49,74618,DB00465,Ketorolac
,21233498,Vss (volume of distribution at steady state),"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.31,74619,DB00465,Ketorolac
,21233498,half-life,"Estimated individual parameters were clearance 1.49 ± 1.12 mL/min/kg, Vss (volume of distribution at steady state) 0.31 ± 0.11 L/kg, and half-life of 236 ± 169 minutes.",Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),min,236,74620,DB00465,Ketorolac
,21233498,clearance,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[ml] / [kg·min],1.52,74621,DB00465,Ketorolac
,21233498,Vss,Estimated population pharmacokinetic parameters were clearance 1.52 mL/min/kg and Vss 0.29 L/kg.,Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233498/),[l] / [kg],0.29,74622,DB00465,Ketorolac
,3598886,ocular bioavailability,The ocular bioavailability of ketorolac was 4% in anesthetized rabbits and was determined by comparing drug concentrations in the aqueous humor after topical application with those obtained after intracameral injection of an equivalent dose of 0.25 mg of ketorolac tromethamine per eye.,Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3598886/),%,4,75893,DB00465,Ketorolac
,15285335,Css(max),"Based on pharmacodynamic/pharmacokinetic correlation in the animal studies, Css(max) and Css(min) of 51.39 and 30.0 microg/mL, respectively, were determined and considered as performance markers for pharmacokinetic evaluation of test formulations.",In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285335/),[μg] / [ml],51.39,77145,DB00465,Ketorolac
,15285335,Css(min),"Based on pharmacodynamic/pharmacokinetic correlation in the animal studies, Css(max) and Css(min) of 51.39 and 30.0 microg/mL, respectively, were determined and considered as performance markers for pharmacokinetic evaluation of test formulations.",In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285335/),[μg] / [ml],30.0,77146,DB00465,Ketorolac
,11812682,volume of distribution at steady state,"Body weight-normalized pharmacokinetic variables did not differ among the age groups and were similar to those reported for adults, including a volume of distribution at steady state of 113 +/- 33 mL/kg (mean +/- SD) and an elimination clearance of 0.57 +/- 0.17 mL x min(-1) x kg(-1).",Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812682/),[ml] / [kg],113,85033,DB00465,Ketorolac
,11812682,elimination clearance,"Body weight-normalized pharmacokinetic variables did not differ among the age groups and were similar to those reported for adults, including a volume of distribution at steady state of 113 +/- 33 mL/kg (mean +/- SD) and an elimination clearance of 0.57 +/- 0.17 mL x min(-1) x kg(-1).",Age-stratified pharmacokinetics of ketorolac tromethamine in pediatric surgical patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812682/),[ml] / [kg·min],0.57,85034,DB00465,Ketorolac
,23143939,C(max),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[ng] / [ml],"2,028.8",95694,DB00465,Ketorolac
,23143939,C(max),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[ng] / [ml],"1,840.1",95695,DB00465,Ketorolac
,23143939,terminal elimination half-life (t(½β)),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,4.52,95696,DB00465,Ketorolac
,23143939,terminal elimination half-life (t(½β)),"Mean (±SD) plasma ketorolac C(max) was 10 % higher (2,028.8 ± 1,069.5 and 1,840.1 ± 995.9 ng/mL) and mean (±SD) terminal elimination half-life (t(½β)) was 37 % longer (4.52 ± 1.14 and 3.31 ± 0.96 h) in the ≥65-years age group than in the <65-years group, respectively.",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,3.31,95697,DB00465,Ketorolac
,23143939,area under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"Mean (±SD) plasma ketorolac area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) was 28 % higher in older subjects than in younger subjects (8,794.8 ± 4,129.4 and 6,890.8 ± 3,448.5 ng · h/mL, respectively).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[h·ng] / [ml],"8,794.8",95698,DB00465,Ketorolac
,23143939,area under the plasma concentration-time curve from time zero to infinity (AUC(∞)),"Mean (±SD) plasma ketorolac area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) was 28 % higher in older subjects than in younger subjects (8,794.8 ± 4,129.4 and 6,890.8 ± 3,448.5 ng · h/mL, respectively).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),[h·ng] / [ml],"6,890.8",95699,DB00465,Ketorolac
,23143939,),"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,6.02,95700,DB00465,Ketorolac
,23143939,residence time,"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,6.02,95701,DB00465,Ketorolac
,23143939,residence time,"Mean (±SD) residence time was 36 % higher in the ≥65-years age group than in the <65-years group (6.02 ± 1.50 and 4.44 ± 1.06 h, respectively) (p = 0.003).",Comparison of intranasal ketorolac tromethamine pharmacokinetics in younger and older adults. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23143939/),h,4.44,95702,DB00465,Ketorolac
,23780501,cumulative percent drug release,"RESULTS & DISCUSSIONS: From the in vitro drug release studies, in case of optimized formulation, the cumulative percent drug release in 15 min (Q15) was found to be 94.34±1.68 where as the conventional tablets showed 28.78±0.82 in 15 min.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,94.34,100306,DB00465,Ketorolac
,23780501,cumulative percent drug release,"RESULTS & DISCUSSIONS: From the in vitro drug release studies, in case of optimized formulation, the cumulative percent drug release in 15 min (Q15) was found to be 94.34±1.68 where as the conventional tablets showed 28.78±0.82 in 15 min.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,28.78,100307,DB00465,Ketorolac
,23780501,initial dissolution rate,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[%] / [min],6.29,100308,DB00465,Ketorolac
,23780501,initial dissolution rate,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[%] / [min],1.92,100309,DB00465,Ketorolac
,23780501,dissolution efficiency,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,53.43,100310,DB00465,Ketorolac
,23780501,dissolution efficiency,The initial dissolution rate and dissolution efficiency of optimized formulation was 6.29%/min and 53.43 but it was 1.92%/min and 14.03 in conventional tablets.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,14.03,100311,DB00465,Ketorolac
,23780501,peak plasma concentration (Cmax),"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng] / [ml],1 248.39,100312,DB00465,Ketorolac
,23780501,Tmax,"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng] / [ml],988.22,100313,DB00465,Ketorolac
,23780501,Tmax,"From the in vivo pharmacokinetic evaluation, the optimized formulation showed peak plasma concentration (Cmax) as 1 248.39 ng/ml at 1 h Tmax, but they were found to be 988.22 ng/ml at 2 h Tmax, in case of conventional tablets.",Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),,2,100314,DB00465,Ketorolac
,23780501,area under the curve,The area under the curve for the optimized and conventional tablets was 3 890.68 and 3 173.07 ng-h/ml.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng-h] / [ml],3 890.68,100315,DB00465,Ketorolac
,23780501,area under the curve,The area under the curve for the optimized and conventional tablets was 3 890.68 and 3 173.07 ng-h/ml.,Formulation and pharmacokinetics of ketorolac tromethamine fast dissolving tablets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780501/),[ng-h] / [ml],3 173.07,100316,DB00465,Ketorolac
,1458761,Cmax,"The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min.",Clinical pharmacokinetics of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),min,20 to 60,102714,DB00465,Ketorolac
,1458761,oral bioavailability,Its oral bioavailability is estimated to range from 80 to 100%.,Clinical pharmacokinetics of ketorolac tromethamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),%,80 to 100,102715,DB00465,Ketorolac
,1458761,volume of distribution,The drug is extensively bound (> 99%) to plasma proteins and has a volume of distribution (0.1 to 0.3 L/kg) comparable with those of other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),[l] / [kg],0.1 to 0.3,102716,DB00465,Ketorolac
,1458761,elimination half-life,The elimination half-life is between 4 and 6h and is moderate in comparison with other NSAIDs.,Clinical pharmacokinetics of ketorolac tromethamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1458761/),h,4 and 6,102717,DB00465,Ketorolac
,21199130,central volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,1130,104745,DB00465,Ketorolac
,21199130,peripheral volume of distribution,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),ml,626,104746,DB00465,Ketorolac
,21199130,clearance from the central compartment,"The population estimates of the R (+) isomer were (%CV): central volume of distribution 1130 (10%) ml, peripheral volume of distribution 626 (25%) ml, and clearance from the central compartment 7.40 (8%) ml·min(-1).",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),[ml] / [min],7.40,104747,DB00465,Ketorolac
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,191,104748,DB00465,Ketorolac
,21199130,elimination half-lives,"Typical elimination half-lives were 191 and 33 min, respectively.",Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21199130/),min,33,104749,DB00465,Ketorolac
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],2.11,104935,DB00465,Ketorolac
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],1.43,104936,DB00465,Ketorolac
,22901775,Clearance,"Clearance in Group IP was higher compared to Groups LP and C (2.11 vs. 1.43 and 1.07 L/h·m(2) respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[h·l] / [m(2],1.07,104937,DB00465,Ketorolac
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.24,104938,DB00465,Ketorolac
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.16,104939,DB00465,Ketorolac
,22901775,Volume of distribution,"Volume of distribution was also increased in Group IP compared to Groups LP and C (0.24 vs. 0.16 and 0.17 L/kg respectively, P<0.05).",Pharmacokinetics of intravenous ketorolac following caesarean delivery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22901775/),[l] / [kg],0.17,104940,DB00465,Ketorolac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,249,106087,DB00465,Ketorolac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,950,106088,DB00465,Ketorolac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,834,106089,DB00465,Ketorolac
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,286,106090,DB00465,Ketorolac
,21380569,V (d),"The predicted V (d) value (21.92 L) is close to the reported value (17.5 L), whereas the CL was predicted by simple allometric approach or with standard correction factors viz., MLP, brain weight, CF1 and CF2.","Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21380569/),l,21.92,106888,DB00465,Ketorolac
,21380569,V (d),"The predicted V (d) value (21.92 L) is close to the reported value (17.5 L), whereas the CL was predicted by simple allometric approach or with standard correction factors viz., MLP, brain weight, CF1 and CF2.","Intravenous prediction of human pharmacokinetic parameters for ketorolac, a non-steroidal anti-inflammatory agent, using allometry approach. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21380569/),l,17.5,106889,DB00465,Ketorolac
,30393871,half-life (T1/2 ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),h,9.78,108171,DB00465,Ketorolac
,30393871,volume of distribution (Vss ),"Using this approach, we identified a long half-life (T1/2 ) of 9.78 hr and a volume of distribution (Vss ) of 0.26 L/kg.",Pharmacokinetics of ketorolac in wild Eastern box turtles (Terrapene carolina carolina) after single intramuscular administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30393871/),[l] / [kg],0.26,108172,DB00465,Ketorolac
,9187531,maximum daily dosage,"The maximum daily dosage is 90mg, and the maximum duration of treatment is 48 hours.",Ketorolac for postoperative pain management in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9187531/),,90,112027,DB00465,Ketorolac
,25523103,end tidal isoflurane concentration,"During surgery, mean end tidal isoflurane concentration was 1.63 (SD 0.24)% and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),%,1.63,119249,DB00465,Ketorolac
,25523103,distribution,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,0.09,119250,DB00465,Ketorolac
,25523103,elimination half-lives,"The distribution and elimination half-lives were 0.09 (SD 0.06) and 4.14 (SD 1.18) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,4.14,119251,DB00465,Ketorolac
,25523103,body clearance,The body clearance was 56.8 (SD 33.1) mL/h/kg.,Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [h·kg],56.8,119252,DB00465,Ketorolac
,25523103,volume of distribution at steady-state,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),[ml] / [kg],323.9,119253,DB00465,Ketorolac
,25523103,mean residence time,"The volume of distribution at steady-state and the mean residence time were 323.9 (SD 115.7) mL/kg and 6.47 (SD 2.86) hours, respectively.",Pharmacokinetics of intravenous ketorolac in cats undergoing gonadectomy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25523103/),h,6.47,119254,DB00465,Ketorolac
,32311454,AUC0-8h,PK studies in rabbits showed significant larger AUC0-8h (646.969 ± 154.326 mg/L•h-1 for KTL-IS IFE and 559.426 ± 103.057 mg/L•h-1 for KTL-BT IFE) than that of ketorolac tromethamine (KTL-T) injectable (286.968 ± 63.045 mg/L•h-1) and approximately 2-fold increases in the elimination t1/2 over KTL-T.,Effective management of acute postoperative pain using intravenous emulsions of novel ketorolac prodrugs: in vitro and in vivo evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311454/),[mg] / [h·l],646.969,130494,DB00465,Ketorolac
,32311454,AUC0-8h,PK studies in rabbits showed significant larger AUC0-8h (646.969 ± 154.326 mg/L•h-1 for KTL-IS IFE and 559.426 ± 103.057 mg/L•h-1 for KTL-BT IFE) than that of ketorolac tromethamine (KTL-T) injectable (286.968 ± 63.045 mg/L•h-1) and approximately 2-fold increases in the elimination t1/2 over KTL-T.,Effective management of acute postoperative pain using intravenous emulsions of novel ketorolac prodrugs: in vitro and in vivo evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311454/),[mg] / [h·l],559.426,130495,DB00465,Ketorolac
,32311454,AUC0-8h,PK studies in rabbits showed significant larger AUC0-8h (646.969 ± 154.326 mg/L•h-1 for KTL-IS IFE and 559.426 ± 103.057 mg/L•h-1 for KTL-BT IFE) than that of ketorolac tromethamine (KTL-T) injectable (286.968 ± 63.045 mg/L•h-1) and approximately 2-fold increases in the elimination t1/2 over KTL-T.,Effective management of acute postoperative pain using intravenous emulsions of novel ketorolac prodrugs: in vitro and in vivo evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32311454/),[mg] / [h·l],286.968,130496,DB00465,Ketorolac
greater,8135994,bioavailability,Ketorolac applied in this way had a bioavailability greater than 80%.,Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135994/),%,80,132170,DB00465,Ketorolac
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.7 to 6.1,141658,DB00465,Ketorolac
,2303585,half-life,"The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4.7 to 6.1 hours for PO and 4.5 to 7.0 hours for IM) and a reduced total plasma clearance compared to the young adult subjects.",Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2303585/),h,4.5 to 7.0,141659,DB00465,Ketorolac
,7952121,run time,Detection was at 325 nm and run time was 10 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,10,142547,DB00465,Ketorolac
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,3.3,142548,DB00465,Ketorolac
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,4.8,142549,DB00465,Ketorolac
,7952121,Retention times,"Retention times of R- and S-ketorolac and of S(+)-naproxen were 3.3, 4.8 and 6.4 min, respectively.",Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,6.4,142550,DB00465,Ketorolac
,7952121,retention time,The metabolite p-hydroxyketorolac was not resolved enantiomerically and had a retention time of 2.2 min.,Determination of ketorolac enantiomers in plasma using enantioselective liquid chromatography on an alpha 1-acid glycoprotein chiral stationary phase and ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952121/),min,2.2,142551,DB00465,Ketorolac
,19161455,half-lives,"Following an i.v. dose, the plasma concentration profiles for the stereoisomers were similar with half-lives of 1.05 +/- 0.62 h for R-KT and 1.05 +/- 0.61 h for S-KT.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,1.05,144223,DB00465,Ketorolac
,19161455,half-lives,"Following an i.v. dose, the plasma concentration profiles for the stereoisomers were similar with half-lives of 1.05 +/- 0.62 h for R-KT and 1.05 +/- 0.61 h for S-KT.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,1.05,144224,DB00465,Ketorolac
,19161455,Clearance,"Clearance values for R- and S-KT after an i.v. dose were 0.53 +/- 0.23 and 0.54 +/- 0.23 L.h/kg, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),[h·l] / [kg],0.53,144225,DB00465,Ketorolac
,19161455,Clearance,"Clearance values for R- and S-KT after an i.v. dose were 0.53 +/- 0.23 and 0.54 +/- 0.23 L.h/kg, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),[h·l] / [kg],0.54,144226,DB00465,Ketorolac
,19161455,terminal half-lives,"Following an oral dose, the terminal half-lives were longer with values of 34.08 +/- 11.81 and 33.97 +/- 12.19 h for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,34.08,144227,DB00465,Ketorolac
,19161455,terminal half-lives,"Following an oral dose, the terminal half-lives were longer with values of 34.08 +/- 11.81 and 33.97 +/- 12.19 h for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),h,33.97,144228,DB00465,Ketorolac
,19161455,bioavailability,"The average bioavailability was 133 +/- 23% for R-KT and S-KT, respectively.",Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19161455/),%,133,144229,DB00465,Ketorolac
,22675252,clearance,"We documented a higher median paracetamol clearance at delivery when compared to 10-15 weeks postpartum (11.7 to 6.4 L/h·m², P < 0.01), even after correction for weight-related changes.",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],11.7 to 6.4,146695,DB00465,Ketorolac
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],2.,146696,DB00465,Ketorolac
,22675252,clearance,"Similar conclusions were drawn for ketorolac: median clearance was higher at delivery with a subsequent decrease (2.03 to 1.43 L/h·m², P < 0.05) in postpartum (17-23 weeks).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1,146697,DB00465,Ketorolac
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],6.4,146698,DB00465,Ketorolac
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],9.6,146699,DB00465,Ketorolac
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.43,146700,DB00465,Ketorolac
,22675252,clearance,"Moreover, postpartum paracetamol clearance was significantly lower when compared to estimates published in healthy young volunteers (6.4 versus 9.6 L/h·m²), while this was not the case for ketorolac (1.43 versus 1.48 L/h·m²).",The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22675252/),[l] / [h·m²],1.48,146701,DB00465,Ketorolac
,2082311,half-life for absorption,It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delays but does not reduce its absorption.,"Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),min,3.8,162671,DB00465,Ketorolac
,2082311,plasma elimination half-life,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),h,5-6,162672,DB00465,Ketorolac
,2082311,Vd beta,"The mean plasma elimination half-life is 5-6 hours, and ketorolac is not extensively distributed outside the vascular compartment (Vd beta 15 L).","Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2082311/),l,15,162673,DB00465,Ketorolac
,23473380,minimal alveolar concentration,"During surgery, mean minimal alveolar concentration of isoflurane was 1.69 ± 0.11%, and normocapnia and spontaneous ventilation were maintained in all animals.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),%,1.69,163499,DB00465,Ketorolac
,23473380,elimination half-life (t½λz ),"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,10.95,163500,DB00465,Ketorolac
,23473380,ClB,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [h·kg],92.66,163501,DB00465,Ketorolac
,23473380,Vdss,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1030.09,163502,DB00465,Ketorolac
,23473380,Vz,"The elimination half-life (t½λz ) and ClB were 10.95 ± 7.06 h and 92.66 ± 84.49 mL/h/kg, respectively, and Vdss and Vz were 1030.09 ± 620.50 mL/kg and 1512.25 ± 799.13 mL/kg, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[ml] / [kg],1512.25,163503,DB00465,Ketorolac
,23473380,AUC(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),[h·μg] / [ml],6.08,163504,DB00465,Ketorolac
,23473380,MRT(0→last),"AUC(0→last) and MRT(0→last) were 6.08 ± 3.28 h × μg/mL and 5.59 ± 2.12 h, respectively.",Pharmacokinetics and perioperative efficacy of intravenous ketorolac in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23473380/),h,5.59,163505,DB00465,Ketorolac
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1889,165338,DB00465,Ketorolac
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),%,0.4,165339,DB00465,Ketorolac
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1212,165340,DB00465,Ketorolac
,23992042,Cmax,"The highest mean concentration of ketorolac was achieved in ISV-304 (0.4%) formulated in DuraSite 2 with a Cmax value of 1889 ± 884 ng/mL, compared to Cmax values for ISV-304 (0.4%) formulated in DuraSite (1212 ± 435 ng/mL) or Acular LS (275 ± 83 ng/mL).",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],275,165341,DB00465,Ketorolac
,23992042,Cmax,ISV-304 (0.2%) formulations also achieved higher AH Cmax values (801 ± 205 ng/mL and 1077 ± 415 ng/mL) compared to Acular LS.,Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],801,165342,DB00465,Ketorolac
,23992042,Cmax,ISV-304 (0.2%) formulations also achieved higher AH Cmax values (801 ± 205 ng/mL and 1077 ± 415 ng/mL) compared to Acular LS.,Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [ml],1077,165343,DB00465,Ketorolac
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],6836,165344,DB00465,Ketorolac
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],5684,165345,DB00465,Ketorolac
,23992042,AUC0.25-24h,"There was a significant increase in drug exposure in the ISV-304 (0.4%) formulated in DuraSite 2 or DuraSite formulations with AUC0.25-24h values 6836 ng/mL*h and 5684 ng/mL*h, respectively, compared to Acular LS with an AUC0.25-24h value of 1424 ng/mL*h.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],1424,165346,DB00465,Ketorolac
,23992042,AUC0.25-24h,"ISV-304 (0.2%) formulations also had high AUC0.25-24h values (3241 ng/mL*h and 4490 ng/mL*h), which were a 2.3-3.2-fold increase over the Acular LS AUC0.25-24h value.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],3241,165347,DB00465,Ketorolac
,23992042,AUC0.25-24h,"ISV-304 (0.2%) formulations also had high AUC0.25-24h values (3241 ng/mL*h and 4490 ng/mL*h), which were a 2.3-3.2-fold increase over the Acular LS AUC0.25-24h value.",Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23992042/),[ng] / [h·ml],4490,165348,DB00465,Ketorolac
,25787064,C max,"From the pharmacokinetic study, the C max of colon-targeted tablets was 3,486.70 ng/ml at T max 10 h, whereas in the case of immediate-release tablets, the C max of 4,506.31 ng/ml at T max 2 h signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787064/),[ng] / [ml],"3,486.70",168602,DB00465,Ketorolac
,25787064,T max,"From the pharmacokinetic study, the C max of colon-targeted tablets was 3,486.70 ng/ml at T max 10 h, whereas in the case of immediate-release tablets, the C max of 4,506.31 ng/ml at T max 2 h signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787064/),,10,168603,DB00465,Ketorolac
,25787064,C max,"From the pharmacokinetic study, the C max of colon-targeted tablets was 3,486.70 ng/ml at T max 10 h, whereas in the case of immediate-release tablets, the C max of 4,506.31 ng/ml at T max 2 h signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787064/),[ng] / [ml],"4,506.31",168604,DB00465,Ketorolac
,25787064,T max,"From the pharmacokinetic study, the C max of colon-targeted tablets was 3,486.70 ng/ml at T max 10 h, whereas in the case of immediate-release tablets, the C max of 4,506.31 ng/ml at T max 2 h signifies the ability of compression-coated tablets to target the colon.",Pharmacokinetics of ketorolac tromethamine compression-coated tablets for colon delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25787064/),,2,168605,DB00465,Ketorolac
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],0.088,171050,DB00465,Ketorolac
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],1.2,171051,DB00465,Ketorolac
,8903001,EC50),"Using the sigmoidal Emax model the mean serum concentration (SD) of ketorolac, 4-methylaminoantipyrine and 4-aminoantipyrine inhibiting platelet TXB2 generation by 50% (EC50) in vitro was found to be 0.088 +/- 0.031, 1.2 +/- 0.3 and 10.2 +/- 3.4 micrograms ml-1, respectively.",The effects on platelet aggregation and prostanoid biosynthesis of two parenteral analgesics: ketorolac tromethamine and dipyrone. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903001/),[μg] / [ml],10.2,171052,DB00465,Ketorolac
,8863274,dose-corrected systemic availability,The dose-corrected systemic availability of the three oral rinses evaluated in the rinse study relative to the peroral capsule was about 15%.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,15,172454,DB00465,Ketorolac
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,59.2,172455,DB00465,Ketorolac
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,86.4,172456,DB00465,Ketorolac
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,1.0,172457,DB00465,Ketorolac
,8863274,relative systemic bioavailabilities,"The dose-corrected relative systemic bioavailabilities for the dentifrice treatments with respect to the 0.1% rinse in the dentifrice study were 59.2% and 86.4% for the 1.0% and 0.15% dentifrices, respectively, indicating that significantly less ketorolac was systemically available from the two dentifrices relative to the oral rinse.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,0.15,172458,DB00465,Ketorolac
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,89.1,172459,DB00465,Ketorolac
,8863274,relative bioavailabilities,The relative bioavailabilities of ketorolac in the GCF after dosing with the dentifrice formulations with respect to the rinse were 89.1% for the 1.0% dentifrice and 19.7% for the 0.15% dentifrice.,Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),%,19.7,172460,DB00465,Ketorolac
,8863274,T1/2,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,0.5,172461,DB00465,Ketorolac
,8863274,plasma half-life,"The T1/2 of ketorolac in the GCF was about 0.5 h for all three treatments, which is significantly less than the plasma half-life of about 5.3 h.",Evaluation of ketorolac concentrations in plasma and gingival crevicular fluid following topical treatment with oral rinses and dentifrices. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8863274/),h,5.3,172462,DB00465,Ketorolac
,10597535,elimination half-life (t1/2 beta),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),h,4.55,181697,DB00465,Ketorolac
,10597535,plasma clearance (Clp),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),[ml] / [kg·min],1.25,181698,DB00465,Ketorolac
,10597535,volume of distribution at steady state (Vss),"Following i.v. administration mean (+/- SD) pharmacokinetic parameters were: elimination half-life (t1/2 beta) = 4.55 h, plasma clearance (Clp) = 1.25 (1.13) mL/kg/min, and volume of distribution at steady state (Vss) = 0.33 (0.10) L/kg.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),[l] / [kg],0.33,181699,DB00465,Ketorolac
,10597535,t1/2 beta,"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),h,4.07,181700,DB00465,Ketorolac
,10597535,time to reach maximum concentration (tmax),"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),min,51.2,181701,DB00465,Ketorolac
,10597535,bioavailability (F),"Mean (+/- SD) p.o. pharmacokinetic values were: t1/2 beta = 4.07 h, time to reach maximum concentration (tmax) = 51.2 (40.6) min, and p.o. bioavailability (F) = 100.9 (46.7)%.",Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10597535/),%,100.9,181702,DB00465,Ketorolac
,32901947,concentration at half maximal effect,"Single dose simulations showed that a previously established analgesic concentration at half maximal effect in adults of 0.37 mg/L, had a mean S-ketorolac concentration of 0.057 mg/L, but a mean S-ketorolac concentration of 0.046 mg/L in infants.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),[mg] / [l],0.37,184487,DB00465,Ketorolac
,32901947,S-ketorolac concentration,"Single dose simulations showed that a previously established analgesic concentration at half maximal effect in adults of 0.37 mg/L, had a mean S-ketorolac concentration of 0.057 mg/L, but a mean S-ketorolac concentration of 0.046 mg/L in infants.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),,0.046,184488,DB00465,Ketorolac
,32901947,EC50,"To match the effective adult S-ketorolac-concentration (0.057 mg/L) in typical infants, the EC50-racemic should be increased to 0.41 mg/L.",Impact of enantiomer-specific changes in pharmacokinetics between infants and adults on the target concentration of racemic ketorolac: A pooled analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32901947/),[mg] / [l],0.41,184489,DB00465,Ketorolac
,26416348,plasma clearance,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[ml] / [kg·min)],8.4,185580,DB00465,Ketorolac
,26416348,volume of distribution at steady-state,Noncompartmental analysis of i.v. dosage indicated a mean plasma clearance of 8.4 (mL/min)/kg and an estimated mean volume of distribution at steady-state of 0.77 L/kg.,"Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),[l] / [kg],0.77,185581,DB00465,Ketorolac
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.0,185582,DB00465,Ketorolac
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,2.6,185583,DB00465,Ketorolac
,26416348,mean residence times,"Noncompartmental analysis of i.v., i.m., and p.o. dosages indicated mean residence times of 2.0, 2.6, and 7.1 h, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),h,7.1,185584,DB00465,Ketorolac
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,71,185585,DB00465,Ketorolac
,26416348,bioavailability,"The drug was rapidly absorbed after i.m. and p.o. administration, and mean bioavailability was 71% and 57% for i.m. and p.o. administration, respectively.","Pharmacokinetics of ketorolac tromethamine in horses after intravenous, intramuscular, and oral single-dose administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26416348/),%,57,185586,DB00465,Ketorolac
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.19-1.22,190047,DB00465,Ketorolac
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.39-1.63,190048,DB00465,Ketorolac
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.28-0.60,190049,DB00465,Ketorolac
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.48-0.88,190050,DB00465,Ketorolac
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],4.50,190051,DB00465,Ketorolac
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],1.40,190052,DB00465,Ketorolac
,32818352,drug loading efficiency,Thermogravimetric analysis revealed that the drug loading efficiency was 4.4% for the SG-Ket-LBL particles.,Single subconjunctival injection formulation using sol-gel mesoporous silica as a controlled release system for drop-free post-cataract surgery care. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32818352/),%,4.4,190830,DB00465,Ketorolac
,33598961,elimination half-life (βT1/2,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),h,11.867,199100,DB00465,Ketorolac
,33598961,maximum concentration (CMAX,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),[μg] / [ml],0.508,199101,DB00465,Ketorolac
,33598961,EC50,"With these methods, we identified a long elimination half-life (βT1/2 = 11.867 hr) but a low maximum concentration (CMAX = 0.508 µg/mL) and concentrations were below the level proposed to be therapeutic in humans (EC50 = 0.1-0.3 μg/mL) for most of the collection period.",Pharmacokinetics of ketorolac in juvenile loggerhead sea turtles (Caretta caretta) after a single intramuscular injection. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33598961/),[μg] / [ml],0.1-0.3,199102,DB00465,Ketorolac
,2787750,maximum potential amount,"The maximum potential amount of ketorolac that an infant may be exposed to daily could range from 3.16 mg to 7.9 mg, assuming a consumption of between 400 ml and 1 l of breast milk.",The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2787750/),,3,200410,DB00465,Ketorolac
,29266539,EC50,An effect site EC50 for analgesia of 0.37 mg.,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),mg,0.37,202737,DB00465,Ketorolac
,29266539,Clearance,Clearance was 2.53 (CV 45.9%) L. h-1. 70 kg-1 and intercompartment clearance was 4.43 (CV 95.6%) L. h-1. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·h·kg],2.53,202738,DB00465,Ketorolac
,29266539,intercompartment clearance,Clearance was 2.53 (CV 45.9%) L. h-1. 70 kg-1 and intercompartment clearance was 4.43 (CV 95.6%) L. h-1. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·h·kg],4.43,202739,DB00465,Ketorolac
,29266539,V1,Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV 30.3%) L. 70 kg-1 and V2 5.53 (CV 47.6%) L. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),[l] / [70·kg],6.89,202740,DB00465,Ketorolac
,29266539,V2,Both central (V1) and peripheral (V2) volumes of distribution decreased with age over the first few years of postnatal life to reach V1 6.89 (CV 30.3%) L. 70 kg-1 and V2 5.53 (CV 47.6%) L. 70 kg-1 .,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),,5.53,202741,DB00465,Ketorolac
larger,29266539,trough concentration,kg-1 every 6 hours maintains a trough concentration larger than 0.37 mg.,The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29266539/),mg,0.37,202742,DB00465,Ketorolac
,8988064,drug concentration at half-maximal effect (EC50),The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),[mg] / [l],0.37,203579,DB00465,Ketorolac
,8988064,first-order rate constant (keo) half-life,The drug concentration at half-maximal effect (EC50) and the first-order rate constant (keo) half-life for pain relief were 0.37 mg/L and 24 minutes.,Population pharmacodynamic model for ketorolac analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8988064/),min,24,203580,DB00465,Ketorolac
,25138250,absolute bioavailability,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),%,68.8,204939,DB00465,Ketorolac
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),h,8.8,204940,DB00465,Ketorolac
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),%,24.8,204941,DB00465,Ketorolac
,25138250,mean residence time,"Pharmacokinetic study of intranasal CPH containing 15% ketorolac tromethamine in rats demonstrated enhanced absolute bioavailability (68.8 ± 23.3%) and prolonged mean residence time (8.8 ± 3.5h) in comparison with the intranasal solution group (24.8 ± 13.8%, 3.9 ± 0.6h).",Enhancement in bioavailability of ketorolac tromethamine via intranasal in situ hydrogel based on poloxamer 407 and carrageenan. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25138250/),h,3.9,204942,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],0.378,219021,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],3.15,219022,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],156.2,219023,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],208.0,219024,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [ml],0.873,219025,DB00465,Ketorolac
,23099451,maximum concentrations (Cmax),"The mean maximum concentrations (Cmax) of ketorolac in the vitreous and RC were 0.378 ± 0.19 μg/mL and 3.15 ± 0.49 μg/g (at 0.5 hours), respectively, in group A; 156.2 ± 20.74 μg/mL (at 0.5 hours) and 208.0 ± 21.67 μg/g (at 1 hours), respectively, in group B; and 0.873 ± 0.34 μg/mL and 56.71 ± 22.64 μg/g (at 0.5 hours), respectively, in group C.","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g],56.71,219026,DB00465,Ketorolac
,23099451,area under the curve (AUC0-t),"In the RC, the area under the curve (AUC0-t) in group B (866.1 ± 52.67 μg/g·h) was higher (P < 0.01) than that in group C (77.10 ± 25.90 μg/g·h).","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g·h],866.1,219027,DB00465,Ketorolac
,23099451,area under the curve (AUC0-t),"In the RC, the area under the curve (AUC0-t) in group B (866.1 ± 52.67 μg/g·h) was higher (P < 0.01) than that in group C (77.10 ± 25.90 μg/g·h).","Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),[μg] / [g·h],77.10,219028,DB00465,Ketorolac
,23099451,elimination half-life (t1/2),The elimination half-life (t1/2) in group B (3.09 hours) was longer (P < 0.01) than that in group C (1.19 hours).,"Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),h,3.09,219029,DB00465,Ketorolac
,23099451,elimination half-life (t1/2),The elimination half-life (t1/2) in group B (3.09 hours) was longer (P < 0.01) than that in group C (1.19 hours).,"Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23099451/),h,1.19,219030,DB00465,Ketorolac
,26056929,peak plasma concentration (Cmax,"From the pharmacokinetic evaluation, the immediate release core mini-tablets reached peak plasma concentration (Cmax of 4532.68 ± 28.14 ng/ml) at 2h Tmax and colon targeted tablets showed Cmax=3782.29 ± 17.83 ng/ml at 12h Tmax.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng] / [ml],4532.68,225477,DB00465,Ketorolac
,26056929,Cmax,"From the pharmacokinetic evaluation, the immediate release core mini-tablets reached peak plasma concentration (Cmax of 4532.68 ± 28.14 ng/ml) at 2h Tmax and colon targeted tablets showed Cmax=3782.29 ± 17.83 ng/ml at 12h Tmax.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng] / [ml],3782.29,225478,DB00465,Ketorolac
,26056929,area under the curve,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng-h] / [ml],"11,278.26",225479,DB00465,Ketorolac
,26056929,area under the curve,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),[ng-h] / [ml],"17,324.48",225480,DB00465,Ketorolac
,26056929,resident time,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),h,3.68,225481,DB00465,Ketorolac
,26056929,resident time,"The area under the curve and mean resident time of core mini-tablets were found to be 11,278.26 ± 132.67 ng-h/ml and 3.68 h respectively while 17,324.48 ± 56.32 ng-h/ml and 10.39 h for compression coated tablets.",Formulation and pharmacokinetics of colon-specific double-compression coated mini-tablets: Chronopharmaceutical delivery of ketorolac tromethamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26056929/),h,10.39,225482,DB00465,Ketorolac
,24512312,Cmax,"After F3 administration to rats, the Cmax (2.2 ± 0.3 µg/ml) was achieved at ∼2 h and the decline in KT concentration was slower.",Pharmacokinetics and analgesic effect of ketorolac floating delivery system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24512312/),[μg] / [ml],2.2,230072,DB00465,Ketorolac
,24251328,LLOQs,"The LLOQs of the method were 0.15 ng on column and 0.31 ng on column for R (+) and S (-) ketorolac, respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),ng,0.15,231458,DB00465,Ketorolac
,24251328,LLOQs,"The LLOQs of the method were 0.15 ng on column and 0.31 ng on column for R (+) and S (-) ketorolac, respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),ng,0.31,231459,DB00465,Ketorolac
,24251328,VD,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [kg],0.12,231460,DB00465,Ketorolac
,24251328,VD,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [kg],0.17,231461,DB00465,Ketorolac
,24251328,CL,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [h·kg],0.017,231462,DB00465,Ketorolac
,24251328,CL,"The median (range) VD and CL of R (+) and S (-) ketorolac were 0.12 l/kg (0.07–0.17), 0.017 l/h/kg (0.12–0.29) and 0.17 (0.09–0.31) l/kg, 0.049 (0.02–0.1) l/h/kg, p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),[l] / [h·kg],0.049,231463,DB00465,Ketorolac
,24251328,elimination half-life (t1/2),"The median (range) elimination half-life (t1/2) of the R (+) and S (-) ketorolac was 5.0 h (2.5–5.8) and 3.1 h (1.8–4.4), p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),h,5.0,231464,DB00465,Ketorolac
,24251328,elimination half-life (t1/2),"The median (range) elimination half-life (t1/2) of the R (+) and S (-) ketorolac was 5.0 h (2.5–5.8) and 3.1 h (1.8–4.4), p = 0.043), respectively.",Development of an enantiomer selective microsampling assay for the quantification of ketorolac suitable for paediatric pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24251328/),h,3.1,231465,DB00465,Ketorolac
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],3,232476,DB00465,Ketorolac
,7848629,Detection limit,Detection limit of the method was 3 ng/ml using 1 ml of plasma and 10 ng/ml using 0.2 ml of blood.,Determination of ketorolac in blood and plasma samples by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7848629/),[ng] / [ml],10,232477,DB00465,Ketorolac
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],180,234456,DB00465,Ketorolac
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],177,234457,DB00465,Ketorolac
,7714743,skin fluxes,"The in vitro skin fluxes were 180, 177, and 14 micrograms/cm2/h for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [cm2·h],14,234458,DB00465,Ketorolac
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],1.265,234459,DB00465,Ketorolac
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.696,234460,DB00465,Ketorolac
,7714743,maximum drug plasma concentrations,"The maximum drug plasma concentrations were 1.265, 0.696, and 0.092 micrograms/mL for formulations A, B, and C, respectively.",Absorption of transdermally delivered ketorolac acid in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7714743/),[μg] / [ml],0.092,234461,DB00465,Ketorolac
,20600724,Cmax,"After NPs administration the mean Cmax, 5.0+/-1.3 mg/l, was attained at 1 h.",Pharmacokinetics of ketorolac loaded to polyethylcyanoacrylate nanoparticles using UPLC MS/MS for its determination in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600724/),[mg] / [l],5.0,235436,DB00465,Ketorolac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.24,241866,DB00465,Ketorolac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0. 29,241867,DB00465,Ketorolac
,10027870,ID50,"The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively.",Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027870/),[mg] / [kg],0.08,241868,DB00465,Ketorolac
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],234,245012,DB00465,Ketorolac
,19628498,peak vitreous concentration,"Ketorolac and diclofenac achieved a peak vitreous concentration of 234 and 73 microg/ml, respectively.",Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [ml],73,245013,DB00465,Ketorolac
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],201,245014,DB00465,Ketorolac
,19628498,peak concentration,The peak concentration of each drug in the retina/choroid was 201 microg/g for ketorolac and 4.1 microg/g for diclofenac.,Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628498/),[μg] / [g],4.1,245015,DB00465,Ketorolac
less,2891477,Tmax,KT was absorbed rapidly (Tmax less than 1.0 hr) and efficiently (greater than 87%) following po and im doses in all species.,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.0,247960,DB00465,Ketorolac
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,1.1,247961,DB00465,Ketorolac
,2891477,plasma half-life,The plasma half-life of ketorolac (K) ranged from 1.1 hr (rabbits) to 6.0 hr (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),h,6.0,247962,DB00465,Ketorolac
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,72.0,247963,DB00465,Ketorolac
,2891477,protein binding,The protein binding of K ranged from 72.0% (mouse) to 99.2% (humans).,"Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2891477/),%,99.2,247964,DB00465,Ketorolac
,21179226,peak concentration (C(max)),"In aqueous humor, the peak concentration (C(max)) and area under the concentration-time curve (AUC(0-τ)) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL following administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[ng] / [ml],389,254287,DB00465,Ketorolac
,21179226,peak concentration (C(max)),"In aqueous humor, the peak concentration (C(max)) and area under the concentration-time curve (AUC(0-τ)) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL following administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[ng] / [ml],211,254288,DB00465,Ketorolac
,21179226,peak concentration (C(max)),"In aqueous humor, the peak concentration (C(max)) and area under the concentration-time curve (AUC(0-τ)) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL following administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [ml],465,254289,DB00465,Ketorolac
,21179226,area under the concentration-time curve (AUC(0-τ)),"In aqueous humor, the peak concentration (C(max)) and area under the concentration-time curve (AUC(0-τ)) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL following administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [ml],939,254290,DB00465,Ketorolac
,21179226,area under the concentration-time curve (AUC(0-τ)),"In aqueous humor, the peak concentration (C(max)) and area under the concentration-time curve (AUC(0-τ)) of ketorolac were, respectively, 389 ng/mL and 939 ng·h/mL following administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 211 ng/mL and 465 ng·hr/mL following administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [ml],465,254291,DB00465,Ketorolac
,21179226,C(max),"In iris-ciliary body, C(max) and AUC(0-τ) of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[ng] / [g],450,254292,DB00465,Ketorolac
,21179226,C(max),"In iris-ciliary body, C(max) and AUC(0-τ) of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[ng] / [g],216,254293,DB00465,Ketorolac
,21179226,C(max),"In iris-ciliary body, C(max) and AUC(0-τ) of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [g],699,254294,DB00465,Ketorolac
,21179226,AUC(0-τ),"In iris-ciliary body, C(max) and AUC(0-τ) of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [g],2040,254295,DB00465,Ketorolac
,21179226,AUC(0-τ),"In iris-ciliary body, C(max) and AUC(0-τ) of ketorolac were, respectively 450 ng/g and 2040 ng·h/g after administration of the CMC-containing 0.45% ketorolac, pH 6.8, and 216 ng/g and 699 ng·h/g after administration of the 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [g],699,254296,DB00465,Ketorolac
,21179226,AUC(0-τ),"PK simulations predicted an AUC(0-τ) of 2910 ng·h/g for twice daily, CMC-containing 0.45% ketorolac, pH 6.8, compared to 725 ng·h/g for 4 times daily, 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [g],2910,254297,DB00465,Ketorolac
,21179226,AUC(0-τ),"PK simulations predicted an AUC(0-τ) of 2910 ng·h/g for twice daily, CMC-containing 0.45% ketorolac, pH 6.8, compared to 725 ng·h/g for 4 times daily, 0.4% ketorolac, pH 7.4.",Ocular pharmacokinetics of 0.45% ketorolac tromethamine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21179226/),[h·ng] / [g],725,254298,DB00465,Ketorolac
,2275236,apparent volume of distribution,Ketorolac is more than 99 percent bound to plasma proteins and has a mean apparent volume of distribution of 0.11-0.25 L/kg.,Ketorolac: a parenteral nonsteroidal antiinflammatory drug. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2275236/),[l] / [kg],0.11-0.25,255157,DB00465,Ketorolac
,17803736,half-lives,"Following an i.v. dose, the plasma concentration profiles of the stereoisomers were similar with half-lives of 5.9 +/- 5.1 h for R-KT and 6.0 +/- 4.9 h for S-KT.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,5.9,257623,DB00465,Ketorolac
,17803736,half-lives,"Following an i.v. dose, the plasma concentration profiles of the stereoisomers were similar with half-lives of 5.9 +/- 5.1 h for R-KT and 6.0 +/- 4.9 h for S-KT.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,6.0,257624,DB00465,Ketorolac
,17803736,Clearance,Clearance values for R- and S-KT after an i.v. dose were 0.0470 +/- 0.0370 and 0.0480 +/- 0.0370 L/h/kg respectively.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),[l] / [h·kg],0.0470,257625,DB00465,Ketorolac
,17803736,Clearance,Clearance values for R- and S-KT after an i.v. dose were 0.0470 +/- 0.0370 and 0.0480 +/- 0.0370 L/h/kg respectively.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),[l] / [h·kg],0.0480,257626,DB00465,Ketorolac
,17803736,terminal half-lives,"After an oral dose, the terminal half-lives were longer than following i.v. administration with values of 14.77 +/- 3.08 and 14.55 +/- 2.95 h for R-KT and S-KT respectively.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,14.77,257627,DB00465,Ketorolac
,17803736,terminal half-lives,"After an oral dose, the terminal half-lives were longer than following i.v. administration with values of 14.77 +/- 3.08 and 14.55 +/- 2.95 h for R-KT and S-KT respectively.",Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),h,14.55,257628,DB00465,Ketorolac
,17803736,oral bioavailability,The average oral bioavailability was 86.5 +/- 20.6% for R-KT and 86.7 +/- 20.3% for S-KT.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),%,86.5,257629,DB00465,Ketorolac
,17803736,oral bioavailability,The average oral bioavailability was 86.5 +/- 20.6% for R-KT and 86.7 +/- 20.3% for S-KT.,Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17803736/),%,86.7,257630,DB00465,Ketorolac
less,19281996,total run-time,The total run-time was less than 18 min.,Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),min,18,268619,DB00465,Ketorolac
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,60,268620,DB00465,Ketorolac
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,72,268621,DB00465,Ketorolac
,19281996,extraction recoveries,"The mean extraction recoveries were 60%, 72% and 76% for paracetamol, R-ketorolac and S-ketorolac, respectively.",Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19281996/),%,76,268622,DB00465,Ketorolac
,17456651,central volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,1200,274021,DB00465,Ketorolac
,17456651,peripheral volume of distribution,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),ml,828,274022,DB00465,Ketorolac
,17456651,clearance from the central compartment,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),[ml] / [min],7.52,274023,DB00465,Ketorolac
,17456651,elimination half-life,"The mean and standard error of the estimates of the R(+) isomer were central volume of distribution 1200 +/- 163 mL (coefficient of variation of interindividual variability, 13.6%), peripheral volume of distribution 828 +/- 108 mL (13.0%), clearance from the central compartment 7.52 +/- 0.7 mL/min (9.3%), and extrapolated elimination half-life 238 +/- 48 min.","Postoperative ketorolac tromethamine use in infants aged 6-18 months: the effect on morphine usage, safety assessment, and stereo-specific pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17456651/),min,238,274024,DB00465,Ketorolac
